Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
In patients with a frequently-relapsing form of kidney disease, relapses decreased approximately five-fold for at least one year after patients took a single dose of rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis. The findings, which will appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), suggest that this drug may provide considerable benefits for patients.
For most children and young adults with a kidney disorder called idiopathic nephrotic syndrome (INS), the disease is thought to arise from an abnormal immune response. Researchers have shown that the drug rituximab can help children with INS that responds to standard treatments consisting of steroids and immunosuppressants. Therefore, rituxmab may allow such patients to discontinue these potentially toxic medications, which can affect children's growth and can increase patients' risks for heart problems, infections, cancer, and other conditions.
But for children and adults whose disease does not respond as well to standard treatments - and is categorized as being "frequently-relapsing" - the benefits of rituximab are less clear.
To investigate, Piero Ruggenenti, MD and Giuseppe Remuzzi, MD, FRCP (Mario Negri Institute for Pharmacological Research, in Italy) led a team that evaluated rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with IMN who had suffered two or more recurrences over the previous year. Patients received one or two doses of rituximab intravenously.
Among the major findings after one year:
The study reveals that rituximab can effectively and safely prevent recurrences and reduce the need for immunosuppression in frequently-relapsing INS.
"Finding that a relatively safe treatment like rituximab may prevent relapses of INS and avoid or reduce the need for steroids and other immunosuppressants may have major clinical implications since rituximab therapy might help limit the complications of both the disease and of concomitant treatments that are often devastating," said Dr. Remuzzi. "Importantly, the results were obtained with one single dose of rituximab, whereas previous protocols recommended the use of four and even more doses," he added.
Study co-authors include Barbara Ruggiero, MD, Paolo Cravedi, MD, Marina Vivarelli, MD, Laura Massella, MD, Maddalena Marasà, MD, Antonietta Chianca, PhD, Nadia Rubis, ResN, Bogdan Ene-Iordache, IngD, Michael Rudnicki, MD, Rosa Maria Pollastro, MD, Giovambattista Capasso, MD, Antonio Pisani, MD, Marco Pennesi, MD, and Francesco Emma, MD, for the "Rituximab in NEphrotic syndrome of steroid-dependent or frequently-relapsing Minimal change disease Or focal segmental glomerulosclerosis (NEMO) Study Group."
Disclosures: This was a fully academic study without involvement of pharmaceutical companies. The "Agenzia Italiana del Farmaco" of the Italian Ministry of Health funded the organization and conduction of the study but had no role in study design or in data collection, analysis, and reporting. The authors have the full responsibility for data analysis and manuscript submission.
The article, entitled "Rituximab In Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome," will appear online at http://jasn.asnjournals.org/.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Urology / Nephrology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
American Society of Nephrology. "Patients with frequently relapsing kidney disease benefit from immune drug." Medical News Today. MediLexicon, Intl., 3 Feb. 2014. Web.
16 Apr. 2014. <http://www.medicalnewstoday.com/releases/271999>
American Society of Nephrology. (2014, February 3). "Patients with frequently relapsing kidney disease benefit from immune drug." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271999.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.